{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:50:51Z","timestamp":1776257451428,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/ftd.0b013e318160ce76","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T06:58:38Z","timestamp":1236236318000},"page":"60-66","source":"Crossref","is-referenced-by-count":22,"title":["Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of Therapy"],"prefix":"10.1097","volume":"30","author":[{"given":"Sofia A","family":"Pereira","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Umbelina","family":"Caixas","sequence":"additional","affiliation":[]},{"given":"Rita M","family":"C\u00f4rte-Real","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Germano","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Lampreia","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia C","family":"Monteiro","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz.","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter and intraindividual variability and clinical effects.","volume":"26","author":"Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","article-title":"Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.","volume":"42","author":"Nettles","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-4347(99)00336-9","article-title":"Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phased high-performance liquid chromatography with ultraviolet detection.","volume":"734","author":"Veldkamp","year":"1998","journal-title":"J Chromatogr B"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2125.1999.00071.x","article-title":"Pharmacokinetic of efavirenz alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.","volume":"48","author":"Villani","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R9-10-20210129","first-page":"551","article-title":"Therapeutic drug monitoring of efavirenz trough levels cannot be estimated on the basis of earlier plasma determinations.","volume":"39","author":"Lopez-Cortes","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-10-20210129","first-page":"309","article-title":"Efavirenz plasma levels for the prediction of treatment failure in heavily pre-treated HIV-1 infected patients.","volume":"7","author":"Langmann","year":"2002","journal-title":"Eur J Med Res"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00007691-200306000-00018","article-title":"Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care.","volume":"25","author":"de Maat","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/01.ftd.0000211825.57984.41","article-title":"An update on therapeutic drug monitoring for antiretroviral drugs.","volume":"28","author":"Back","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00003088-200443130-00002","article-title":"Practical guidelines to interpret plasma concentrations of antiretroviral drugs.","volume":"43","author":"Kappelhoff","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF03189968","article-title":"Analytical methods validadation: Bioavailability, Bioequivalence and pharmacokinetic studies.","volume":"16","author":"Shah","year":"1991","journal-title":"Eur J Drug Met Pharmacokinet"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.48.3.979-984.2004","article-title":"Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy.","volume":"48","author":"Brundage","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00007691-200108000-00012","article-title":"Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.","volume":"23","author":"Marzolini","year":"200","journal-title":"Ther Drug Monit"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00002030-200305020-00029","article-title":"Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.","volume":"17","author":"Boffito","year":"2003","journal-title":"AIDS"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2165\/00003088-200544120-00005","article-title":"High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.","volume":"44","author":"Goujard","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2006.02619.x","article-title":"Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.","volume":"61","author":"Pereira","year":"2006","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318160ce76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:35:37Z","timestamp":1620952537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200802000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318160ce76","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}